Update on Consumer Healthcare Joint Venture with Pfizer
GlaxoSmithKline plc (LSE/NYSE: GSK) today has announced that the shareholder resolution relating to the transaction between GSK and Pfizer Inc to create a Consumer Healthcare Joint Venture, which was announced on 19 December 2018 was approved at a General Meeting held by GSK today. 99.85% of shareholders voted for the resolution.
Completion of the Transaction remains subject to certain antitrust and regulatory approvals and customary closing conditions.
GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Principal risks and uncertainties' in the company's Annual Report on Form 20-F for 2018.
Find out more
Image and video library
Images can be downloaded in low and high resolution. Our YouTube channel offers a regularly updated collection of GSK videos
Consumer Healthcare Joint Venture
On 19 December 2018 we announced our agreement with Pfizer to combine our consumer health businesses into a new world-leading Joint Venture.